• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Terazol (terconazole) Creme and Suppositories

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2013

Summary View

WARNINGS

  • Anaphylaxis and toxic epidermal necrolysis have been reported during terconazole therapy. Terazol therapy should be discontinued if anaphylaxis or toxic epidermal necrolysis develops

ADVERSE REACTIONS

Post-marketing Experience..... new section added